Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics is an emerging biopharmaceutical company primarily focused on the development and commercialization of a proprietary oral drug candidate, MDX, to treat ADHD and other cognitive dysfunctions including Fragile X Syndrome. The most common available treatments for ADHD are stimulants that increase the brain chemicals dopamine and norepinephrine. Stimulants have significant side effects, and are classified as controlled substances which have significant potential for misuse, abuse and addiction. MDX is not a stimulant, and works with a different mechanism of action. MDX is a proprietary, combined rapid onset release formulation of the chemical Pyridoxine Pyroglutamate.
  • TickerARCT
  • ISINUS03969T1097
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
 PRESS RELEASE
ARCT Arcturus Therap... (Health Care)

Arcturus Therapeutics Announces Fourth Quarter and Full Year 2020 Fina...

SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced its financial results for the quarter and full year ended December 31, 2020 and provided a corporate update. “Based on highly promising clinical data from our Phase 1/2 study and emerging mRNA vaccine immunological data, we are advancing ARCT-021 for further development in Phase 3. We ...

 PRESS RELEASE
ARCT Arcturus Therap... (Health Care)

Arcturus Therapeutics Acquires Exclusive License to mRNA Manufacturing...

SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company has acquired an exclusive license from Alexion Pharmaceuticals to certain patent-pending inventions relating to nucleic acid purification technologies. Since the Company’s inception in 2013, Arcturus has been building proprietary expertise related to the manufacture of...

 PRESS RELEASE
ARCT Arcturus Therap... (Health Care)

Arcturus Therapeutics to Report Fourth Quarter and Year-End 2020 Finan...

SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it will provide a corporate overview and release its financial results for the quarter and year ended December 31, 2020 after the market close on March 1 and will also host a conference call and webcast at 4:30 pm Eastern Time on Monday, March 1, 2021. Monday, March 1 @ 4:30 p.m....

 PRESS RELEASE
ARCT Arcturus Therap... (Health Care)

Arcturus Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will participate in upcoming investor conferences. BIO CEO & Investor Digital Conference Presentation Date: Friday, February 12, 2021 Time: 12:00 p.m. ET Raymond James 42nd Annual Institutional Investors Conference Fireside Chat Date: Wednesday, March 3, 20...

 PRESS RELEASE
ARCT Arcturus Therap... (Health Care)

Arcturus Therapeutics to Present at Upcoming Investor Conference

SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will participate in a panel discussion taking place at the 13th Annual Biotech Showcase™ Investor Conference: Infectious Disease - COVID-19 Vaccines: All things impacted by COVID-19: The pursuit for an effective vaccine developed at a pandemic pace Panel Discussion ...

 PRESS RELEASE
ARCT Arcturus Therap... (Health Care)

Arcturus Therapeutics Announces Fourth Quarter and Full Year 2020 Fina...

SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced its financial results for the quarter and full year ended December 31, 2020 and provided a corporate update. “Based on highly promising clinical data from our Phase 1/2 study and emerging mRNA vaccine immunological data, we are advancing ARCT-021 for further development in Phase 3. We ...

 PRESS RELEASE
ARCT Arcturus Therap... (Health Care)

Arcturus Therapeutics Acquires Exclusive License to mRNA Manufacturing...

SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company has acquired an exclusive license from Alexion Pharmaceuticals to certain patent-pending inventions relating to nucleic acid purification technologies. Since the Company’s inception in 2013, Arcturus has been building proprietary expertise related to the manufacture of...

 PRESS RELEASE
ARCT Arcturus Therap... (Health Care)

Arcturus Therapeutics to Report Fourth Quarter and Year-End 2020 Finan...

SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it will provide a corporate overview and release its financial results for the quarter and year ended December 31, 2020 after the market close on March 1 and will also host a conference call and webcast at 4:30 pm Eastern Time on Monday, March 1, 2021. Monday, March 1 @ 4:30 p.m....

 PRESS RELEASE
ARCT Arcturus Therap... (Health Care)

Arcturus Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will participate in upcoming investor conferences. BIO CEO & Investor Digital Conference Presentation Date: Friday, February 12, 2021 Time: 12:00 p.m. ET Raymond James 42nd Annual Institutional Investors Conference Fireside Chat Date: Wednesday, March 3, 20...

 PRESS RELEASE
ARCT Arcturus Therap... (Health Care)

Arcturus Therapeutics to Present at Upcoming Investor Conference

SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will participate in a panel discussion taking place at the 13th Annual Biotech Showcase™ Investor Conference: Infectious Disease - COVID-19 Vaccines: All things impacted by COVID-19: The pursuit for an effective vaccine developed at a pandemic pace Panel Discussion ...

 PRESS RELEASE
ARCT Arcturus Therap... (Health Care)

Arcturus Therapeutics Announces Fourth Quarter and Full Year 2020 Fina...

SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced its financial results for the quarter and full year ended December 31, 2020 and provided a corporate update. “Based on highly promising clinical data from our Phase 1/2 study and emerging mRNA vaccine immunological data, we are advancing ARCT-021 for further development in Phase 3. We ...

 PRESS RELEASE
ARCT Arcturus Therap... (Health Care)

Arcturus Therapeutics Acquires Exclusive License to mRNA Manufacturing...

SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company has acquired an exclusive license from Alexion Pharmaceuticals to certain patent-pending inventions relating to nucleic acid purification technologies. Since the Company’s inception in 2013, Arcturus has been building proprietary expertise related to the manufacture of...

 PRESS RELEASE
ARCT Arcturus Therap... (Health Care)

Arcturus Therapeutics to Report Fourth Quarter and Year-End 2020 Finan...

SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it will provide a corporate overview and release its financial results for the quarter and year ended December 31, 2020 after the market close on March 1 and will also host a conference call and webcast at 4:30 pm Eastern Time on Monday, March 1, 2021. Monday, March 1 @ 4:30 p.m....

 PRESS RELEASE
ARCT Arcturus Therap... (Health Care)

Arcturus Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will participate in upcoming investor conferences. BIO CEO & Investor Digital Conference Presentation Date: Friday, February 12, 2021 Time: 12:00 p.m. ET Raymond James 42nd Annual Institutional Investors Conference Fireside Chat Date: Wednesday, March 3, 20...

 PRESS RELEASE
ARCT Arcturus Therap... (Health Care)

Arcturus Therapeutics to Present at Upcoming Investor Conference

SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will participate in a panel discussion taking place at the 13th Annual Biotech Showcase™ Investor Conference: Infectious Disease - COVID-19 Vaccines: All things impacted by COVID-19: The pursuit for an effective vaccine developed at a pandemic pace Panel Discussion ...

 PRESS RELEASE
ARCT Arcturus Therap... (Health Care)

Arcturus Therapeutics Announces Fourth Quarter and Full Year 2020 Fina...

SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced its financial results for the quarter and full year ended December 31, 2020 and provided a corporate update. “Based on highly promising clinical data from our Phase 1/2 study and emerging mRNA vaccine immunological data, we are advancing ARCT-021 for further development in Phase 3. We ...

 PRESS RELEASE
ARCT Arcturus Therap... (Health Care)

Arcturus Therapeutics Acquires Exclusive License to mRNA Manufacturing...

SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company has acquired an exclusive license from Alexion Pharmaceuticals to certain patent-pending inventions relating to nucleic acid purification technologies. Since the Company’s inception in 2013, Arcturus has been building proprietary expertise related to the manufacture of...

 PRESS RELEASE
ARCT Arcturus Therap... (Health Care)

Arcturus Therapeutics to Report Fourth Quarter and Year-End 2020 Finan...

SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it will provide a corporate overview and release its financial results for the quarter and year ended December 31, 2020 after the market close on March 1 and will also host a conference call and webcast at 4:30 pm Eastern Time on Monday, March 1, 2021. Monday, March 1 @ 4:30 p.m....

 PRESS RELEASE
ARCT Arcturus Therap... (Health Care)

Arcturus Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will participate in upcoming investor conferences. BIO CEO & Investor Digital Conference Presentation Date: Friday, February 12, 2021 Time: 12:00 p.m. ET Raymond James 42nd Annual Institutional Investors Conference Fireside Chat Date: Wednesday, March 3, 20...

 PRESS RELEASE
ARCT Arcturus Therap... (Health Care)

Arcturus Therapeutics to Present at Upcoming Investor Conference

SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will participate in a panel discussion taking place at the 13th Annual Biotech Showcase™ Investor Conference: Infectious Disease - COVID-19 Vaccines: All things impacted by COVID-19: The pursuit for an effective vaccine developed at a pandemic pace Panel Discussion ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch